Accelerate your CDx development in ovarian cancer

Use a distributable HRD assay for your global research and CDx development

Unlock the benefits of our partnership with Myriad

We are partnering with Myriad Genetics to develop a distributable research kit for homologous recombination deficiency (HRD) testing and a distributable IVD kit for clinical development once a pharma partner is identified. The assay shows promise to advance personalized medicine and targeted treatments in multiple solid tumor cancers, including ovarian cancer, based on the tumor’s unique genetic profile.

Female scientists discussing research in modern laboratory

Get actionable results for informed targeted therapies

The assay – based on our QIAseq next-generation sequencing (NGS) technology and Myriad’s MyChoice CDx design – harnesses our combined expertise in assay development. MyChoice CDx is a single-site PMA based centralized testing service for analyzing HRD in tumors.

Our QIAseq panels enable efficient and accurate NGS library preparation. Over 4 million samples have been processed with QIAseq panels for cancer testing applications.

Accurate determination of HRD status is crucial for informed treatment decisions. MyChoice CDx assesses HRD status resulting from mutations in genes such as BRCA1 and BRCA2 and calculates a genomic instability score (GIS). This GIS enables targeted ovarian cancer therapies – such as LYNPARZA (olaparib) by AstraZeneca – to be matched to the right patient at the right time.

Read about MyChoice CDx
Learn more about our partnership with Myriad
Read press release
Our experience with regulatory authorities worldwide sets us apart. This means we can navigate the regulatory path, satisfy requirements and drive your success.

Your partner from development to commercialization

Our wealth of experience in global companion diagnostics (CDx) development means we can navigate the regulatory path, satisfy regulatory requirements and drive your success.

We will oversee the development, regulatory approval and global distribution of the HRD assay to molecular laboratories and pharmaceutical companies. Like MyChoice CDx, our HRD kits, including an IVD kit, will include Myriad’s GIS as well as the related algorithms and analysis software.

We work together with you to support your clinical trials and CDx co-development programs and further your HRD research.

“Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics. Together, we aim to broaden the accessibility of HRD tests, allowing an increasing number of cancer patients to benefit from tailored treatments.”
Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area, QIAGEN